A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

May 29, 2026

Study Completion Date

May 29, 2026

Conditions
Type 1 Diabetes
Interventions
DRUG

VX-264

Allogeneic human stem cell-derived islets.

Trial Locations (16)

15213

University of Pittsburgh Medical Center Montefiore, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

33136

UHealth Diabetes Research Institute, Miami

53792

University of Wisconsin, Madison

60637

University of Chicago, Chicago

02114

Massachusetts General Hospital, Boston

Unknown

University of Alberta, Edmonton, Edmonton

Montreal Clinical Research Institute, Montreal

Toronto General Hospital (TGH), Toronto

Vancouver General Hospital, Vancouver

Dresden Center for Islet Transplantation, Dresden

IRCCS Ospedale San Raffaele, Milan

Leiden University, Leiden

Hopiteaux Universitaires de Geneve, Geneva

Churchill Hospital, Headington

Royal Victoria Infirmary, Newcastle upon Tyne

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY